Review





Similar Products

96
Bio-Rad rat anti mouse monoclonal f4 80
Rat Anti Mouse Monoclonal F4 80, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f4/Rat+anti+Mouse+F4%2F80/10__22203_slash_ecm__v033a11-129-8-16
Average 96 stars, based on 1 article reviews
rat anti mouse monoclonal f4 80 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

98
Cell Signaling Technology Inc anti f4 80
Anti F4 80, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f4/F4%2F80+XP+Rabbit+mAb/pmc13770902-39-29-30
Average 98 stars, based on 1 article reviews
anti f4 80 - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

96
Proteintech f4 80
F4 80, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f4/F4%2F80+Antibody/pm42875944-344-6-7
Average 96 stars, based on 1 article reviews
f4 80 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

97
Santa Cruz Biotechnology f4 80
Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b <t>+</t> <t>F4/80</t> + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.
F4 80, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f4/F4%2F80+Antibody/pmc13748629-100-40-43
Average 97 stars, based on 1 article reviews
f4 80 - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

96
Proteintech anti f4 80
Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b <t>+</t> <t>F4/80</t> + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.
Anti F4 80, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f4/F4%2F80+Antibody/pm43004435-113-16-17
Average 96 stars, based on 1 article reviews
anti f4 80 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Proteintech tongue sections
Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b <t>+</t> <t>F4/80</t> + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.
Tongue Sections, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f4/F4%2F80+Antibody/pm43002206-201-3-12
Average 96 stars, based on 1 article reviews
tongue sections - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Proteintech fitc conjugated anti f4 80 antibody
Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b <t>+</t> <t>F4/80</t> + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.
Fitc Conjugated Anti F4 80 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f4/F4%2F80+Antibody/pm42985724-416-15-20
Average 96 stars, based on 1 article reviews
fitc conjugated anti f4 80 antibody - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

98
Cell Signaling Technology Inc f4 80
Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b <t>+</t> <t>F4/80</t> + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.
F4 80, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f4/F4%2F80+XP+Rabbit+mAb/pm42988024-103-19-21
Average 98 stars, based on 1 article reviews
f4 80 - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

95
Selleck Chemicals 10058 f4
Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b <t>+</t> <t>F4/80</t> + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.
10058 F4, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/f4/10058-F4/pm42980512-49-61-62
Average 95 stars, based on 1 article reviews
10058 f4 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

Image Search Results


Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b + F4/80 + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.

Journal: Cancer Communications

Article Title: Combined Immunotherapy and Hybrid Dose-Fraction Radiotherapy for Driver-Negative Metastatic NSCLC: A Phase II Trial with Parallel Preclinical Studies

doi: 10.34133/cancomm.0065

Figure Lengend Snippet: Myeloid–fibroblast interaction and Spp1 + macrophage analysis in metastatic lesions. (A) UMAP plot of myeloid-subtype cells from scRNA-seq data of lung tissues from the Control, anti-PD-1, ISABR, and IHBRT groups ( n = 3/group), colored by cell type. (B) Average expression and percentage of cells expressing representative marker genes across the indicated myeloid-subtype cells. (C) Bar plot showing the relative proportion of cells from 4 treatment groups for myeloid subtypes ( n = 3/group). (D) Information flow showing signaling pathways ranked based on differences between ISABR and IHBRT. (E) Communication of the SPP1 signaling pathway network between myeloid subtypes and fibroblast cells. (F) Volcano plot showing differentially expressed genes of macrophages between IHBRT and ISABR. Red: significantly up-regulated genes, P < 0.05 and log 2 (fold change) > 0.25. Blue: significantly down-regulated genes, P < 0.05 and log 2 (fold change) < −0.25. Gray: ns. (G) Kaplan–Meier curves of OS in TCGA-LUAD and TCGA-LUSC cohorts. Patients were dichotomized by the SPP1 + macrophage signature score at the data-driven optimal cutoff (high score, n = 334; low score, n = 670). (H) Representative flow cytometry plots (left) and the proportion (right) of Spp1 + in CD11b + F4/80 + cells in lung tissue ( n ≥ 3/group). (I) Representative mIF images in lung tissue on day 21. Differential expression analysis was performed using the Wilcoxon rank-sum test with Benjamini–Hochberg correction. Survival curves were compared using the log-rank test; HRs were estimated using a Cox proportional hazards model. Error bars indicate mean ± SD. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001. Abbreviations: ANOVA, analysis of variance; anti-PD-1, anti-programmed cell death protein 1 antibody; CD11b, cluster of differentiation 11b; DC, dendritic cell; IHBRT, ICI plus Hybrid-RT; ISABR, ICI plus SABR; KEGG, Kyoto Encyclopedia of Genes and Genomes; mIF, multiplex immunofluorescence; OS, overall survival; scRNA-seq, single-cell RNA sequencing; SD, standard deviation; SPP1, secreted phosphoprotein 1; TCGA-LUAD, The Cancer Genome Atlas-lung adenocarcinoma; TCGA-LUSC, The Cancer Genome Atlas-lung squamous cell carcinoma; UMAP, uniform manifold approximation and projection; ns, not significant.

Article Snippet: Sections were incubated overnight at 4 °C with primary antibodies against CD8 (Cat. #ab217344, Abcam), CD3 (Cat. #ab135372, Abcam), NK1.1 (Cat. #ab289542, Abcam), CXCR3 (Cat. #ab288437, Abcam), C-X-C motif chemokine ligand 10 (CXCL10, Cat. #10937-1-AP, Proteintech), GZMB (Cat. #13588-1-AP, Proteintech), F4/80 (Cat. #sc-52664, Santa Cruz), and secreted phosphoprotein 1 (SPP1, Cat. #sc-21742, Santa Cruz).

Techniques: Analysis, Control, Expressing, Marker, Protein-Protein interactions, Flow Cytometry, Tissue, Quantitative Proteomics, Multiplex Assay, Immunofluorescence, Single Cell, RNA Sequencing, Standard Deviation